| __timestamp | BeiGene, Ltd. | Ultragenyx Pharmaceutical Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 6930000 | 10811000 |
| Thursday, January 1, 2015 | 7311000 | 33001000 |
| Friday, January 1, 2016 | 20097000 | 64936000 |
| Sunday, January 1, 2017 | 62602000 | 99909000 |
| Monday, January 1, 2018 | 195385000 | 127724000 |
| Tuesday, January 1, 2019 | 388249000 | 161524000 |
| Wednesday, January 1, 2020 | 600176000 | 182933000 |
| Friday, January 1, 2021 | 990123000 | 219982000 |
| Saturday, January 1, 2022 | 1277852000 | 278139000 |
| Sunday, January 1, 2023 | 1504501000 | 309799000 |
In pursuit of knowledge
In the competitive world of biotechnology, managing expenses is crucial for sustaining growth and innovation. This analysis compares the Selling, General, and Administrative (SG&A) expenses of BeiGene, Ltd. and Ultragenyx Pharmaceutical Inc. from 2014 to 2023. Over this period, BeiGene's SG&A expenses skyrocketed by over 21,600%, reflecting its aggressive expansion and scaling efforts. In contrast, Ultragenyx's expenses grew by approximately 186%, indicating a more measured approach. By 2023, BeiGene's expenses were nearly five times those of Ultragenyx, highlighting differing strategic priorities. This divergence underscores the varied paths companies take in the biotech sector, balancing between rapid growth and sustainable management. As the industry evolves, these trends offer insights into how financial strategies can impact long-term success.
Selling, General, and Administrative Costs: Bristol-Myers Squibb Company vs Ultragenyx Pharmaceutical Inc.
Operational Costs Compared: SG&A Analysis of GSK plc and BeiGene, Ltd.
Cost Management Insights: SG&A Expenses for Biogen Inc. and BeiGene, Ltd.
Cost Management Insights: SG&A Expenses for BeiGene, Ltd. and Neurocrine Biosciences, Inc.
Breaking Down SG&A Expenses: BeiGene, Ltd. vs Insmed Incorporated
Breaking Down SG&A Expenses: BeiGene, Ltd. vs Catalent, Inc.
Comparing Innovation Spending: BeiGene, Ltd. and Ultragenyx Pharmaceutical Inc.
Cost Management Insights: SG&A Expenses for BeiGene, Ltd. and CRISPR Therapeutics AG
Selling, General, and Administrative Costs: BeiGene, Ltd. vs MannKind Corporation
Operational Costs Compared: SG&A Analysis of BeiGene, Ltd. and Geron Corporation
Comparing SG&A Expenses: Insmed Incorporated vs Ultragenyx Pharmaceutical Inc. Trends and Insights
Ultragenyx Pharmaceutical Inc. vs Amphastar Pharmaceuticals, Inc.: SG&A Expense Trends